Evidence map›Paper›PMID 39534092›Full record

ArticleFrontiers in oncology2024

Primary hepatoid adenocarcinoma of the lung in patient with silicosis: a case report and literature review.

Lipeng Huang, Chaoyang Chen, Qingyu Sun, Zhichen Yu, Xiaoyan Wang, Xinle Wang, Shuoqi Yang, Luming Jin, Liang Bu

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lipeng HuangDepartment of Thoracic Surgery, Xiang'an Hospital of Xiamen University, Xiamen, Fujian, China.
Chaoyang ChenDepartment of Thoracic Surgery, Xiang'an Hospital of Xiamen University, Xiamen, Fujian, China.
Qingyu SunDepartment of Thoracic Surgery, Xiang'an Hospital of Xiamen University, Xiamen, Fujian, China.
Zhichen YuDepartment of Thoracic Surgery, Xiang'an Hospital of Xiamen University, Xiamen, Fujian, China.
Xiaoyan WangDepartment of Thoracic Surgery, Xiang'an Hospital of Xiamen University, Xiamen, Fujian, China.
Xinle WangDepartment of Thoracic Surgery, Xiang'an Hospital of Xiamen University, Xiamen, Fujian, China.
Shuoqi YangDepartment of Thoracic Surgery, Xiang'an Hospital of Xiamen University, Xiamen, Fujian, China.
Luming JinDepartment of Thoracic Surgery, Xiang'an Hospital of Xiamen University, Xiamen, Fujian, China.
Liang BuDepartment of Thoracic Surgery, Xiang'an Hospital of Xiamen University, Xiamen, Fujian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Hepatoid adenocarcinoma of the lung (HAL) is a special type of adenocarcinoma originating from the lung with adenoid- and hepatocyte-like differentiation. HAL is rare in clinical practice. Here, we present the case of a patient with HAL. Case presentation: A 59-year-old man was admitted to the hospital 4 days because of lung mas observed. Chest computed tomography (CT) revealed a lobulated mass shadow in the right lower lobe, approximately 3.5 × 3.3 cm in size. CT-guided percutaneous biopsy of the right lower lung was performed. The pathological results indicated a moderately to poorly differentiated adenocarcinoma. The patient underwent thoracoscopic right middle and lower lobectomy and systematic lymph node dissection. The postoperative pathology was primary HAL, with the staging of T2bN2M0 (stage III A). Recurrence-free survival and overall survival were 6 and 19 months, respectively Preoperatively, the level of alpha-fetoprotein was negative; however, after recurrence, it increased to 87.8. Conclusion: Pulmonary hepatoid adenocarcinoma is a rare subtype of malignant lung tumor, combined silicosis is more rare. Early surgical intervention can benefit patients in the early stages of the disease, whereas chemotherapy remains the main systemic treatment modality for postoperative and advanced stages. With the increasing popularity of genetic testing, it is important to focus on improving genetic examination.

Indexed as

genetic testinghepatoid adenocarcinomalung malignancylung metastasissilicosis

Identifiers

PMID39534092
PMCPMC11554529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.